https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-03-05-00-00-3054815
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with...
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic...
https://www.goodrx.com/wayrilz/what-is
Wayrilz (rilzabrutinib): Uses, Side Effects, Dosage & Reviews
Learn about Wayrilz (rilzabrutinib) usage and dosing. Read the latest news and reviews about the drug as well as potential side effects and popular...
side effectswayrilzrilzabrutinibusesdosage
https://www.sanofi.com/en/media-room/press-releases/2020/2020-11-18-06-15-00-2128828
Press Release: Rilzabrutinib granted FDA Fast Track Designation for treatment of immune...
Rilzabrutinib granted FDA Fast Track...
fda fast trackpress release
https://www.sanofi.com/en/media-room/press-releases/2024/2024-05-22-17-15-00-2886776
Media Update: New results from rilzabrutinib phase 2 study show potential to be first advanced oral...
New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma Late-breaking data presented at...